Celgene

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018 Juno Therapeutics was acquired by Celgene for $9 billion.

Juno Therapeutics

Lenalidomide (trade name Revlimid) is a derivative of thalidomide introduced in 2004.  It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Along with several other drugs developed in recent years, lenalidomide has significantly improved overall survival in myeloma (which formerly carried a poor prognosis), although toxicity remains an issue for users. It costs $163,381 per year for the average patient.

Revlimid

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.   There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.   In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Bristol-Myers

Bristol-Myers Squibb Company (NYSE:BMY ) Jefferies London Healthcare Conference November 19, 2024 4:30 AM ET Company Participants David Elkins - CFO Unidentified Company Representative On to the next fireside chat. And again, thanks, everyone, for your attendance.

Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)

Bristol-Myers Squibb Company (NYSE:BMY ) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Company Participants Samit Hirawat - EVP, Chief Medical Officer, Global Drug Development Robert Plenge - EVP, Chief Research Officer Conference Call Participants Seamus Fernandez - Guggenheim Seamus Fernandez Okay. So, in the interest of staying on time here, really pleased to have Bristol Myers Squibb joining us.

Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)

Bristol-Myers Squibb Company (NYSE:BMY ) Q3 2024 Results Conference Call October 31, 2024 8:00 AM ET Company Participants Chuck Triano - Senior Vice President, Investor Relations Chris Boerner - Board Chair & Chief Executive Officer David Elkins - Chief Financial Officer Adam Lenkowsky - Chief Commercialization Officer Samit Hirawat - Chief Medical Officer & Head of Global Drug Development Conference Call Participants Evan Seigerman - BMO Capital Markets Chris Shibutani - Goldman Sachs Chris Schott - JPMorgan Luisa Hector - Berenberg Geoff Meacham - Citibank Carter Gould - Barclays Trung Huynh - UBS Steve Scala - Cowen Courtney Breen - Bernstein Seamus Fernandez - Guggenheim Securities Matt Phipps - William Blair David Risinger - Leerink Partners Akash Tewari - Jefferies James Shin - Deutsche Bank Olivia Brayer - Cantor Sean McCutchen - Raymond James Srikripa Devarakonda - Truist Securities Operator Good day, and welcome to the Bristol-Myers Squibb Third Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript

Bristol-Myers Squibb Company (NYSE:BMY ) Wells Fargo 2024 Healthcare Conference September 6, 2024 12:00 AM ET Company Participants Adam Lenkowsky - Chief Commercialization Officer Conference Call Participants Mohit Bansal - Wells Fargo Cerena Chen - Wells Fargo Mohit Bansal All right. Good morning on a Friday.

Bristol-Myers Squibb Company (BMY) Wells Fargo 2024 Healthcare Conference (Transcript)

Bristol-Myers Squibb Company (NYSE:BMY ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 1:05 PM ET Company Participants Chris Boerner - Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Okay, great. Thanks for joining us everybody.

Bristol-Myers Squibb Company (BMY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Bristol-Myers Squibb Company (NYSE:BMY ) Q2 2024 Earnings Conference Call July 26, 2024 8:00 AM ET Company Participants Tim Power - Vice President, Head of Investor Relations Chris Boerner - Board Chair and Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Adam Lenkowsky - Executive Vice President, Chief Commercialization Officer Samit Hirawat - Executive Vice President, Chief Medical Officer, Global Drug Development Conference Call Participants Chris Schott - JPMorgan Luisa Hector - Berenberg Chris Shibutani - Goldman Sachs Tim Anderson - Wolfe Research Evan Seigerman - BMO Capital Markets Carter Gould - Barclays Seamus Fernandez - Guggenheim Securities Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Steve Scala - TD Cowen Trung Huynh - UBS Matthew Phipps - William Blair Olivia Brayer - Cantor Fitzgerald Steve Chesney - Redburn Atlantic James Shin - Deutsche Bank Kripa Devarakonda - Truist Securities Sean McCutcheon - Raymond James Alexandria Hammond - Bank of America Operator Good day and welcome to the Bristol Myers Squibb Second Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.

Bristol-Myers Squibb Company (BMY) Q2 2024 Earnings Call Transcript

Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 11:20 AM ET Company Participants Chris Boerner - Board Chair and Chief Executive Officer Conference Call Participants Chris Shibutani - Goldman Sachs Good morning, still, I think, everybody, and welcome. We are very pleased that you're joining us here on the Second Day of the Goldman Sachs Healthcare Conference.

Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY ) Bank of America Global Healthcare Conference 2024 May 15, 2024 2:20 PM ET Company Participants David Elkins – Executive Vice President and Chief Financial Officer Conference Call Participants Geoff Meacham – Bank of America Chen Yang – Bank of America Geoff Meacham I'm Geoff Meacham. I'm the senior biopharma analyst, and I have Charlie from my team on stage with me as well.

Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript

Bristol-Myers Squibb Company. (NYSE:BMY ) Guggenheim Securities Radiopharmaceuticals Day May 13, 2024 11:00 AM ET Company Participants Ben Hickey - President RayzeBio, Head of Mirati Conference Call Participants Unidentified Analyst Alright, Ben, let's continue here with Ben Hickey now from Bristol.

Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript)

Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)

Bristol-Myers Squibb Company (NYSE:BMY ) 44th Annual TD Cowen Healthcare Conference March 4, 2024 9:50 AM ET Company Participants Roland Chen - SVP and Head, Cardiovascular and Neuroscience Development, Global Drug Development Conference Call Participants Steve Scala - TD Cowen Steve Scala Well, good morning once again. We're delighted to have Bristol-Myers Squibb here at the Cowen 44th Annual Healthcare Conference, representing the company is Roland Chen, who's Senior Vice President and Head of Immunology, Cardiology, or Cardiovascular and Neuroscience Development.

Bristol-Myers Squibb Company (BMY) 44th Annual TD Cowen Healthcare Conference (Transcript)

Bristol-Myers Squibb Company (BMY) Q4 2023 Earnings Call Transcript

Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript)

Alnylam Pharmaceuticals

argenx

Blueprint Medicines

Exelixis

Genmab - ADR

Incyte

Seagen

Sarepta Therapeutics

Alexion Pharma

Horizon Pharma

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.

5 Biotech Acquisition Targets To Accumulate In 2024

NEW ORLEANS, Nov. 24, 2021 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in a securities class action lawsuit against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE: BMY), if they received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS' acquisition of Celgene on November 20, 2019.

BRISTOL MYERS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY

NEW ORLEANS, Nov. 17, 2021 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 6, 2021 to file lead plaintiff applications in a securities class action lawsuit against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE: BMY), if they received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS' acquisition of Celgene on November 20, 2019.  This action is pending in the United States District Court for the Southern District of New York.

BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY

LOS ANGELES, Nov. 1, 2021 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bristol-Myers Squibb Company ("Bristol-Myers" or "the Company") (NYSE: BMY) on behalf of former shareholders of Celgene Corporation ("Celgene") (Nasdaq: CELG) who received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) for violations of the federal securities laws. Investors who received CVRs in exchange for their shares pursuant to Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019 ("Merger") are encouraged to contact the firm before December 6, 2021.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Boston, Massachusetts--(Newsfile Corp. - October 28, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed against Bristol-Myers Squibb Company alleging violations of the Federal Securities Laws. The case is currently in the lead plaintiff stage. All former Celgene Corporation (NASDAQ: CELG) shareholders that received Contingent Value Rights ("CVRs") in exchange for their Celgene shares pursuant to Bristol Myers's $74 billion acquisition of Celgene on November 20, 2019,...

Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company

Boston, Massachusetts--(Newsfile Corp. - October 23, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed against Bristol-Myers Squibb Company alleging violations of the Federal Securities Laws. The case is currently in the lead plaintiff stage. All former Celgene Corporation (NASDAQ: CELG) shareholders that received Contingent Value Rights ("CVRs") in exchange for their Celgene shares pursuant to Bristol Myers's $74 billion acquisition of Celgene on November 20, 2019,...

CELG Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company

NEW YORK--(BUSINESS WIRE)--ENTWISTLE & CAPPUCCI LLP FILES A SECURITIES CLASS ACTION COMPLAINT AGAINST BRISTOL-MYERS SQUIBB COMPANY

Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Bristol-Myers Squibb Company

China's influence in the global pharmaceutical industry is on the rise

Celgene-Backed Antengene Climbs On Hong Kong Debut

Investors and analysts who questioned the wisdom of Bristol-Myers Squibb Co.’s (NYSE:BMY) purchase of Celgene last year for $74 billion might want to reconsider their opinion about the largest health care takeover in history.

Celgene Deal Starting to Pay Off Big for Bristol-Myers

Regulatory Deep Dive On The Celgene CVR

The Food and Drug Administration moved its action date on  liso-cell back by three months.

Former Celgene Shareholders' Contingent Value Rights Slip Further Away

Reblozyl recently became the first treatment for adults with lower-risk myelodysplastic syndromes.

News for Celgene Stock (CELG)